April 22–23, 2026 — Chongqing Precision Biotech Co., Ltd. was recognized with the “Most Innovative Pharmaceutical Company” award at the 7th BIONNOVA Biopharmaceutical Innovators Forum, held at Zhangjiang Science Hall in Shanghai.

The annual forum convened more than 300 international experts, over 260 exhibitors, and more than 10,000 participants from across the biopharmaceutical ecosystem to discuss emerging trends, clinical translation, and development strategies for innovative medicines.At the Frontiers of In Vivo Cell Therapy Forum, Prof. Qian Cheng, Chairman and Chief Scientist of Chongqing Precision Biotech, delivered a featured presentation titled “R&D Strategies and Research Progress in In Vivo CAR-T.”

In his presentation, Prof. Qian reviewed multiple approaches for implementing in vivo CAR-T technologies and shared recent progress by the company in targeted delivery vector design, gene-editing safety controls, and in vivo immune modulation strategies. He noted that in situ generation of CAR-T cells may represent a promising direction for next-generation immunotherapy, while key challenges remain in delivery efficiency, durability, and controllability.